|
|
 |
| |
|
Home > Drug Companies > AstraZeneca: A New Leader in the Pharmaceutical Industry
AstraZeneca: A New Leader in the Pharmaceutical Industry
AstraZeneca is a pharmaceutical company founded in 1999. This company merged of a Swedish company called Astra AB and a British group called Zeneca Group PLC. Since its foundation, these two companies share one mission: be the number one in the industry. AstraZeneca provides patients, customers, governments, and communities with the best products thanks to the effort of many people working on researching, marketing, and selling.
AstraZeneca’s major segments are gastrointestinal, cardiovascular and respiratory treatments. However, this company has a leading place in the oncology and anesthesia markets. AstraZeneca has a solid financial structure. Besides, this enterprise produces innovative and effective medicines manufactured to improve people’s health around the world. Its more important products include cancer treatment (Casodex, Arimidex, and Faslodex), gastrointestinal illnesses (Nexium), and asthma (Symbicort). Other treatments offered are hypertension, high cholesterol, migraine, and schizophrenia. These products are sold in more than 100 countries.
Research and develop are vital actions for AstraZeneca. In fact, more than 11,900 people work in the investigation field. The company has seven R&D centers located in the United States, the United Kingdom, Sweden, Japan, France, Canada, and India. Last year, this company invested $3.8 billion in research and development.
Today AstraZeneca employs 64,000 people in 20 countries. It has 30 manufacturing plants around the world. Its headquarters offices are located in London, UK. In spite of being a new company, in our days, AstraZeneca competes next to the most powerful pharmaceutical companies of the world.
Back to Drug Companies
|
|
|
|
|
|
|
|